

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2951444

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
SEQUENCE:	2
CONVEYING PARTY DATA	
Name	Execution Date
PDL BIOPHARMA, INC.	02/05/2008
RECEIVING PARTY DATA	
Name:	ABBOTT LABORATORIES
Street Address:	100 ABBOTT PARK ROAD
City:	ABBOTT PARK
State/Country:	ILLINOIS
Postal Code:	60064
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14101145
CORRESPONDENCE DATA	
Fax Number:	(617)374-0055
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 374-3700
Email:	MChinappi@yankwich.com
Correspondent Name:	YANKWICH & ASSOCIATES, P.C.
Address Line 1:	201 BROADWAY
Address Line 4:	CAMBRIDGE, MASSACHUSETTS 02139
ATTORNEY DOCKET NUMBER:	ABT-111.1 US-2 (8370USD1)
NAME OF SUBMITTER:	THOMAS R. BERKA, REG. NO. 39,606
SIGNATURE:	/Thomas R. Berka/
DATE SIGNED:	07/23/2014
Total Attachments: 2	
source=Assignment (PDL BioPharma to Abbott) ABT-111.1 US#page1.tif	
source=Assignment (PDL BioPharma to Abbott) ABT-111.1 US#page2.tif	

ASSIGNMENT

I/We,

PDL BioPharma, Inc.

residing at

1400 Seaport Drive, Redwood City, CA 94063 (US)

for good and valuable consideration, receipt of which is hereby acknowledged, have assigned, sold and transferred to and do hereby assign, sell and transfer to Abbott Laboratories, a corporation organized and existing under the laws of the State of Illinois and having an office and a place of business at 100 Abbott Park Road, Abbott Park, IL 60064, its successors and assigns:

1) the entire right, title and interest in the United States and in all countries throughout the world in and to any and all my/our inventions and discoveries disclosed in United States Application Ser. No. 11/899,819, filed 7 September 2007 {Atty. Docket No. 8370.US.P1} and International Application Ser. No. PCT/US2007/19660, filed 7 September 2007 {Atty. Docket No. 8370.WO.O1} and designating AP, EA, EP, OA, AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BY, BZ, CA, CF, CG, CH and LI, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GW, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MC, MD, MG, MK, ML, MN, MR, MW, MX, MZ, NE, NI, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, SN, SY, SZ, TD, TG, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, VC, ZA, ZM and ZW; all entitled: "IL-13 BINDING PROTEINS", including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof, and any substitute applications therefor;

2) the full and complete right to file patent applications in the name of Abbott Laboratories, its designee, or in my name at the election of Abbott Laboratories or its designee, on the aforesaid inventions, discoveries and applications in all countries of the world;

3) the entire right, title and interest in and to any Letters Patent which may issue thereon in the United States or in any other country of the world and any renewals, revivals, reissues, reexaminations and extensions of the same; and

4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.


We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to Abbott Laboratories as the assignee of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by us had this assignment, sale and transfer not been made.

We further agree, at any time, upon the request of Abbott Laboratories, to execute and to deliver to Abbott Laboratories any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.

We further agree at any time to execute and to deliver upon request to Abbott Laboratories such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of Abbott Laboratories under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

ASSIGNORS:

(1)



Andrew L. Guggenime
Chief Financial Officer
PDL BioPharma, Inc.

ACKNOWLEDGEMENT:

On this 5th day of February, 2008, Andrew Guggenime, Chief Financial Officer, of PDL BioPharma, Inc., and authorized to sign on behalf of PDL BioPharma, Inc., personally appeared before me, executed the foregoing Assignment, and duly acknowledged to me that such Assignment was executed by his/her free act and deed for the uses and purposes therein expressed.



Witness signature

LILLY L. KO

Witness name (please print)